Point72 Europe (London) LLP Biomarin Pharmaceutical Inc Transaction History
Point72 Europe (London) LLP
- $1.35 Billion
- Q1 2025
A detailed history of Point72 Europe (London) LLP transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Point72 Europe (London) LLP holds 54,580 shares of BMRN stock, worth $3.27 Million. This represents 0.29% of its overall portfolio holdings.
Number of Shares
54,580
Previous 60,741
10.14%
Holding current value
$3.27 Million
Previous $3.99 Million
3.36%
% of portfolio
0.29%
Previous 0.25%
Shares
2 transactions
Others Institutions Holding BMRN
# of Institutions
668Shares Held
184MCall Options Held
1.24MPut Options Held
957K-
Black Rock Inc. New York, NY22.7MShares$1.36 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA19MShares$1.14 Billion0.03% of portfolio
-
Primecap Management CO Pasadena, CA17.8MShares$1.07 Billion1.06% of portfolio
-
Dodge & Cox San Francisco, CA15MShares$896 Million0.65% of portfolio
-
Viking Global Investors LP10.8MShares$647 Million2.55% of portfolio
About BIOMARIN PHARMACEUTICAL INC
- Ticker BMRN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,824,000
- Market Cap $11.1B
- Description
- BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...